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two consecutive antigen capture or 
RT-PCR tests on blood specimens are 
negative.5 We did not find any PHE 
document providing formal criteria for 
discharge of patients with conﬁ rmed 
EVD. Thus, none of these widely 
referenced health agencies provide 
recom mendations for discharging EVD 
patients cared for outside Africa.
Of 22 patients with EVD discharged 
from hospitals in Europe and the USA, 
discharge criteria were available for 
14 cases (table). Diﬀ erent virological 
criteria for discharge were applied 
between and within the same country, 
ranging from two consecutive blood 
specimens testing negative for Ebola 
virus RNA by RT-PCR assay to the 
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During the recent epidemic of Ebola 
virus disease (EVD) in west Africa,1 
several health-care and aid workers 
infected with EVD were evacuated 
to Europe and the USA, where local 
transmission occurred in occupationally 
exposed health-care workers. 
Preparation for discharge requires an 
organised and evidence-based approach 
to ensure that the patient, health-
care workers, family, and community 
are protected at all times. The risk of 
infection to others after discharge in 
the community and of unexpected 
late clinical events for the patient make 
discharge policies diﬃ  cult to formulate.2
To suggest a framework for 
developing international consensus 
on criteria for safe discharge of EVD 
patients from hospital in high-
income countries, we searched the 
websites of WHO, the US Centers for 
Disease Control and Prevention (CDC), 
the European Centre for Disease 
Prevention and Control (ECDC), and 
Public Health England (PHE) for 
hospital discharge criteria using the 
search terms “EVD discharge”, “EVD 
management”, “Ebola discharge”, 
and “Ebola management”. We also 
searched PubMed, ProMed, and 
Embase for all published clinical 
reports on EVD patients cared for 
out of Africa during the current EVD 
outbreak using the search terms 
(“Ebola” OR “EVD”) AND (“case” OR 
“cases” OR “case-report” OR “report” 
OR “patient” OR “patients”) in the 
title or abstract. The search dates 
were January, 2014, to July, 2015. We 
also added unpublished data about 
EVD patients treated at the National 
Institute for Infectious Diseases (INMI) 
Lazzaro Spallanzani in Rome, Italy.
WHO guidelines recommended that, 
in west Africa, the discharge of an EVD 
case be based on improvement of 
the clinical conditions together with, 
if laboratory testing is available, a 
negative blood RT-PCR for Ebola virus 
RNA.3 The US CDC listed eight criteria 
to consider when deciding whether to 
discharge people under investigation 
for Ebola virus disease, but no 
guideline was provided for conﬁ rmed 
cases.4 The criteria included resolution 
of all symptoms and having no clinical 
laboratory results consistent with EVD. 
The ECDC has currently removed from 
the public access domain of its website 
a previously published expert opinion 
document on EVD discharge criteria 
for EU countries. This document 
recommended that EVD cases should 
remain in isolation until recovery 
from clinical symptoms of EVD and 
Centre Day of 
Discharge* 
Discharge criteria Comments
1 Atlanta 30 2 negative RT-PCR for EBOV on 
blood 24 h apart
Patient had positive urine RT-PCR for EBOV on 
day 28. Unspeciﬁ ed results on other biological ﬂ uids.
2 Atlanta 29 2 negative RT-PCR for EBOV on 
blood 24 h apart
Patient had repeated negativity of RT-PCR for 
EBOV in urine. Unspeciﬁ ed results on other 
biological ﬂ uids.
3 Atlanta 44 Negative blood and urine RT-PCR 
for EBOV on serial specimens
At discharge semen positive for EBOV on RT-PCR 
and culture
4 Dallas†
Bethesda‡
15 Repeated negative RT-PCR for EBOV 
on blood
Throat, rectal, vaginal, urine, and sweat samples 
negative for EBOV on RT-PCR
5 Dallas†
Atlanta‡
14 Repeated negative blood and urine 
RT-PCR for EBOV 
Skin and vaginal swabs negative for EBOV on 
RT-PCR
6 Omaha 28 3 serial blood samples free of EBOV Unspeciﬁ ed result of tests in other biological 
specimens
7 Omaha 20 3 serial blood samples free of EBOV Unspeciﬁ ed result of tests in other biological 
specimens
8 New York 22 2 negative RT-PCR for EBOV on 
blood
Unspeciﬁ ed result of tests in other biological 
specimens
9 Hamburg 40 All cultures of RT-PCR positive 
samples of body ﬂ uids free of 
infectious virus for 20 days
At discharge patient had negative RT-PCR in 
plasma and urine; positive RT-PCR on sweat
10 Frankfurt NA Repeated negative blood RT-PCR 
for EBOV 
Urine and stool samples also negative RT-PCR 
for EBOV
11 Madrid 34 Repeated negative RT-PCR for EBOV 
of all body ﬂ uid samples
Unspeciﬁ ed body site and number of samples
12 Rome 44 Repeated negative RT-PCR for EBOV 
of all body ﬂ uid samples apart from 
semen
Patient’s throat, sweat, ocular, and stool samples 
negative for EBOV on RT-PCR 
13 Rome 31 Repeated negative RT-PCR for EBOV 
of all body ﬂ uid samples apart from 
semen
Patient’s blood, urine, throat, sweat, ocular, 
sputum, and stool samples negative for EBOV on 
RT-PCR 
14 Geneva 19 Repeated negative RT-PCR for EBOV 
of all body ﬂ uid samples
Patient’s blood, urine, sweat, ocular, saliva, and 
stool samples negative for EBOV on RT-PCR 
EBOV=Ebola virus RNA. Atlanta=Emory University Hospital, Atlanta, GA, USA. Dallas=Texas Health Presbyterian Hospital, Dallas, TX, USA. 
Bethesda=National Institutes of Health Clinical Center, Bethesda, MD, USA. Omaha=Nebraska Medical Center, Omaha, NE, USA. New York=Bellevue 
Hospital Center, New York, NY, USA. Hamburg=University Medical Center, Hamburg, Germany. Frankfurt=University Hospital, Frankfurt, Germany. 
Madrid=La Paz Carlos III University Hospital, Madrid, Spain. Rome=INMI Lazzaro Spallanzani, Rome, Italy. Geneva=Geneva University Hospitals, 
Geneva, Switzerland. *From onset of illness. †Admitted to. ‡Transferred to.
Table: Discharge criteria for 14 patients with Ebola virus disease managed at hospitals in Europe and the USA
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convalescent person to the household, 
nor on commencement of social and 
professional activities are available.
The definition of cure of the EVD 
patient is an ongoing debate: a viable 
Ebola virus was isolated in the aqueous 
humour of the eye of a US patient 
(patient 3, table) with acute panuveitis 
nine weeks after Ebola virus clearance 
from blood.9 In the longer term, 
further research is needed to assess 
the presence of infective viruses in 
EVD convalescent patients to establish 
evidence-based criteria and guidelines 
for discharge.10 An important need 
exists for the scientific community 
to reach a consensus and develop 
universal guidelines using the available 
evidence base to deﬁ ne the discharge 
criteria for EVD patients, taking into 
consideration the epidemic context 
and available resources in low-income 
and high-income countries. With this 
aim, the INMI Lazzaro Spallanzani is 
starting an international consultation 
on the critical issues of patients’ 
discharge outside outbreak settings.
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absence of Ebola virus in cell culture 
of several biological samples. In all but 
one patient, negative RT-PCR assays on 
biological samples were considered as 
common minimum requirements for 
discharging patients in the community. 
Patient 9, according to the German 
guidelines, was released from the 
hospital only when no infectious virus 
was isolated in cell culture. At the INMI 
Lazzaro Spal lanzani in Rome, Italy, 
patients 12 and 13 were considered 
to be convalescent at day 28 and 
17 from illness onset, respectively, since 
clinical symptoms resolved completely 
and RT-PCR on the blood became 
negative.6 Despite this, the institute 
only discharged patients 12 and 13 
after achieving negative RT-PCR assay 
on urine and other body ﬂ uids.
The key issues for further discussion 
are: (1) the clinical and virological cri-
teria for discontinuing strict isolation 
and stepping down to routine hospital 
practice; (2) the clinical and virological 
criteria for discharge from hospital; (3) 
the virological criteria for resumption 
of household, community, and profes-
sional activities; (4) the follow-up of 
clinical and virological parameters 
during the convalescent phase; and 
(5) the deﬁ nition of “cured”. The value 
of a positive biomolecular assay in the 
absence of data on the infectivity of 
the same biological sample remains 
unclear and discharge criteria need to 
be considered in the context of viral 
persistence after clinical recovery. Before 
discharging patients home, preliminary 
steps to scale down isolation 
precautions to routine in-hospital 
practices were applied diﬀ erently in the 
reported cases; in most cases, negative 
Ebola virus blood RT-PCR and lack 
of gastrointestinal symptoms were 
considered the minimum required 
criteria. The persistence of Ebola virus 
in semen 9 months after the onset 
of disease7,8 necessitates condom use 
or avoidance of sexual intercourse, 
although the duration of these 
preventive measures have not been 
deﬁ ned. No clear data on the virological 
criteria on the readmission of the 
